# A Study to Evaluate the Safety, Tolerability, and Drug Levels of Orally Administered BMS-986368 in Healthy Participants, Healthy Elderly Participants, and Healthy Participants of Japanese Ethnicity

> **NCT06411730** · PHASE1 · COMPLETED · sponsor: **Celgene** · enrollment: 56 (actual)

## Conditions studied

- Healthy Participants

## Interventions

- **DRUG:** BMS-986368

## Key facts

- **NCT ID:** NCT06411730
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-05-31
- **Primary completion:** 2024-10-28
- **Final completion:** 2024-10-28
- **Target enrollment:** 56 (ACTUAL)
- **Last updated:** 2024-11-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06411730

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06411730, "A Study to Evaluate the Safety, Tolerability, and Drug Levels of Orally Administered BMS-986368 in Healthy Participants, Healthy Elderly Participants, and Healthy Participants of Japanese Ethnicity". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06411730. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*